A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions Among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT)
概览
- 阶段
- 3 期
- 干预措施
- Laboratory Biomarker Analysis
- 疾病 / 适应症
- AIDS-Related Human Papillomavirus Infection
- 发起方
- AIDS Malignancy Consortium
- 入组人数
- 536
- 试验地点
- 6
- 主要终点
- Occurrence of cervical high-grade squamous intraepithelial lesions (HSIL) or cervical cancer
- 状态
- 已完成
- 最后更新
- 3个月前
概览
简要总结
This randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV. Vaccines made from HPV peptides or antigens may help the body build an effective immune response to kill the HPV virus and prevent cervical lesions from developing or coming back after being removed.
详细描述
At screening, potential participants will be tested for cervical human papillomavirus (HPV) infection (GeneXpert hrHPV assay and HPV DNA PCR) and undergo cervical colposcopy to confirm the absence of cervical cancer. If eligible, the participant will be randomized to receive either the 9-valent HPV vaccine or saline placebo. Participants will return 4 and 26 weeks later for the second dose of vaccine or placebo. At week 4, participants will have cervical colposcopy and undergo cryotherapy or loop electrosurgical excisional procedure (LEEP) as appropriate. Participants undergoing cervical cryotherapy will have cervical biopsies before the treatment. Participants will be followed with HPV testing (Gene Xpert and HPV DNA PCR) at weeks 26, 52, 78, and 104, and will have cervical cytology and colposcopy with biopsies at weeks 26, 52, and 104.
研究者
入排标准
入选标准
- •HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load, or documentation of receipt of antiretroviral therapy; Note: the term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a western blot or a plasma HIV-1 RNA viral load
- •HPV positive by the GeneXpert hrHPV assay with HPV16, HPV 18/45, or HPV31/33/35/52/58 detected; Note: participants who are hrHPV positive with only HPV51/59 or HPV 39/68/56/66 detected are not eligible
- •Receipt of ART for at least 180 days prior to randomization
- •Participants of childbearing potential, defined as a sexually mature woman who: (1) has not undergone a hysterectomy or bilateral oophorectomy or (2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months), must have a negative urine or serum pregnancy test within 3 weeks prior to enrollment and agree to use an effective form of contraception (e.g., barrier contraception or hormonal contraception), delaying pregnancy for at least 12 months and ideally for the duration of the study; Note: those willing to participate delay pregnancy for at least 6 months, while receiving the recombinant human papillomavirus nonavalent (9vHPV) vaccine (or placebo)
- •If the participant is of childbearing potential, she should be at least 3 months postpartum
- •Karnofsky score \>= 70%
- •Ability to understand and the willingness to sign a written informed consent document
排除标准
- •Current sexually transmitted infection (STI) requiring treatment (women may participate after adequate treatment, at the discretion of the treating provider)
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to Gardasil or Gardasil 9
- •Uncontrolled intercurrent illness that would limit compliance with study requirements
- •Prior hysterectomy with removal of the cervix
- •Prior treatment for cervical HSIL
- •Prior history of cervical, vulvar, or vaginal cancer
- •Cervical, vulvar, or vaginal lesions suspicious for cancer based on clinical appearance (e.g. necrotic, ulcerated, and/or fungating masses), unless biopsies show no invasive cancer
- •Known bleeding diathesis
- •Prior HPV vaccination
- •Current or planned use of anticoagulants other than aspirin or non-steroidal anti-inflammatory agents
研究组 & 干预措施
Arm I, recombinant HPV 9-valent vaccine
Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
干预措施: Laboratory Biomarker Analysis
Arm I, recombinant HPV 9-valent vaccine
Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
干预措施: Recombinant Human Papillomavirus Nonavalent Vaccine
Arm II, saline
Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
干预措施: Laboratory Biomarker Analysis
Arm II, saline
Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
干预措施: Saline
结局指标
主要结局
Occurrence of cervical high-grade squamous intraepithelial lesions (HSIL) or cervical cancer
时间窗: After week 4 study visit to week 52 post-randomization
For each arm (vaccine and placebo), the event rate will be estimated using its point estimate and 95% Poisson confidence intervals. Poisson regression analyses will be used to compare the two arms with respect to event rate. In addition, time to event from week 4 to 52 will be described using the Kaplan-Meier method for each arm, and the two arms will be compared with respect to time to event using the log-rank test.
次要结局
- Occurrence of cervical HSIL from weeks 52-104(After week 52 to week 104)
- Role of ART use as a predictor of sustained absence(At baseline and week 4)
- Role of vaccination use as a predictor of sustained absence(At baseline and week 4)
- Prevalent vulvar HSIL or cancer(Up to week 4)
- Incident cervical vaccine type HPV infections defined as infections at 2 consecutive timepoints and assessed using type specific HPV DNA polymerase chain reaction (PCR)(Up to week 104)
- Role of plasma HIV-1 RNA as a predictor of sustained absence(At baseline and week 4)
- Role of age as a predictor of sustained absence(At baseline and week 4)
- Role of sexual behavior as a predictor of sustained absence(At baseline and week 4)
- Abnormal cervical cytology(Baseline, week 26, 52, and 104)
- Incident vulvar HSIL or cancer(Up to week 104)
- Role of baseline types and quantity of HPV as predictors of sustained absence(At baseline and week 4)
- Role of CD4+ cell count as a predictor of sustained absence(At baseline and week 4)
- Role of presence of HSIL at baseline as a predictor of sustained absence(At baseline and week 4)
- Clinical and demographic factors associated with incident vulvar HSIL or cancer(Up to week 104)